Article Text

Download PDFPDF

P159/O30 OLT1177™, an oral NLRP3 inflammasome inhibitor, inhibits acute joint inflammation and circulating IL 1β during gout flares in humans
  1. V Klück1,
  2. M Janssen2,
  3. TL Jansen2,
  4. IW Tengesdal1,3,
  5. K Schraa1,
  6. DB Skouras4,
  7. C Marchetti3,
  8. CA Dinarello1,3,
  9. LA Joosten1,5
  1. 1Department of Internal Medicine, RadboudUMC, Nijmegen
  2. 2Department of Rheumatology, VieCuri MC, Venlo, Netherlands
  3. 3Department of Medicine, University of Colorado, Aurora
  4. 4Olatec Therapeutics LLC, New York, USA
  5. 5Department of Medical Genetics, ‘Iuliu Haţieganu’ University of Medicine and Pharmacy, Cluj Napoca, Romania


Career situation of first and presenting author Young investigator.

Introduction Gout flares are characteristically mediated by the pro-inflammatory cytokine interleukin (IL)-1β.1 Uptake of monosodium urate (MSU) crystals by macrophages activates the nucleotide-binding domain and leucine-rich repeat containing family, pyrin domain containing 3 (NLRP3) inflammasome, which converts intracellular pro-interleukin-1β (pro-IL-1β) to mature bioactive IL-1β by proteolytic cleavage. Deposition of MSU crystals alone is not sufficient to trigger a gout flare. In the presence of concomitant pro-inflammatory stimuli, i.e. Toll-Like Receptor (TLR) agonists, transcription of il-1β gene is induced and pro-IL-1β is rapidly converted into its active form. IL-1β binds to its receptor (IL-1R1) and induces a cascade of secondary inflammatory mediators including prostaglandins, cytokines and chemokines. Recently, OLT1177™, a β-sulfonyl nitrile compound, safe in humans, was shown to inhibit the NLRP3 inflammasome, reverse the metabolic cost of inflammation and inhibit joint inflammation in murine models of acute arthritis.2 3

Objectives To explore the mechanism by which oral OLT1177™ inhibits joint inflammation in humans with gout flares.

Methods 29 patients with a gout flare were treated within 4 days after the start of the symptoms with three different doses of OLT1177™ for 7 days (EudraCT: 2016-000943-14). Blood was drawn at baseline, days 3, 7 and 14 (7 days after finishing treatment). Haematology, hsCRP and SAA were measured as markers for systemic inflammation. Plasma was collected for assessment of circulating cytokines. Peripheral blood mononuclear cells (PBMCs ) were isolated and cultured under unstimulated or stimulated conditions with a TLR ligands (Pam3Cys and LPS) in combination with MSU crystals after which intra- and extracellular cytokine production was assessed.

Results Plasma IL-1β are increased in samples from intercritical gout patients and individuals with gout flares when compared to healthy controls (healthy controlshsCRP and SAA and acute phase proteins of individuals treated with OLT1177™ during a gout flare show a dose-dependent reduction during course of treatment. Circulating IL–1β and IL–6, but not TNFα, was reduced and stimulated cytokine production of PBMCs declined during treatment. In unstimulated PBMCs on day 3, ratio of intracellular pro-IL-1β and IL-1β revealed inhibition of the NLRP3 inflammasome by oral OLT1177™. Moreover, in vitro and ex vivo data show OLT1177™ spontaneously increases the level of IL-1 receptor antagonist (IL-1Ra).

Conclusions Oral OLT1177™, safe in humans, inhibits inflammation and increases systemic IL-1Ra concentrations in patients with an acute gout flare by inhibiting the NLRP3 inflammasome product, IL–1b.


  1. Dinarello CA. How interleukin-1beta induces gouty arthritis. Arthritis Rheum 2010;62(11):3140–4.

  2. Marchetti C, et al. OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA 2018;115(7):E1530–E1539.

  3. Marchetti C, et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther 2018;20(1):169.

Acknowledgements We wish to acknowledge the gout patients who participated as well as Daniëlle Poeth and Dorine Baselmans for their commitment to the conduct of this study.

Potential investigators conflict of interest DS is Founder and CEO of Olatec, CD is CSO and SAB member of Olatec, LJ is SAB member of Olatec.

Disclosure of Interest None declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.